Zulesso(Brexanolone) ÀǾàǰ ÀλçÀÌÆ® ¹× ½ÃÀå Àü¸Á(-2032³â)
ZULRESSO Drug Insight and Market Forecast - 2032
»óǰÄÚµå : 1381102
¸®¼­Ä¡»ç : DelveInsight Business Research LLP
¹ßÇàÀÏ : 2023³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 30 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,750 £Ü 3,805,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,125 £Ü 5,707,000
PDF (2-3 User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 3¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,500 £Ü 7,610,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,250 £Ü 11,415,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º» º¸°í¼­´Â ¹Ì±¹ Zulesso(Brexanolone) ½ÃÀå¿¡ ´ëÇØ Á¶»ç ºÐ¼®ÇßÀ¸¸ç, ÀÛ¿ë±âÀü, ¿ë¹ý ¹× ¿ë·®, ¿¬±¸°³¹ß Ȱµ¿¿¡ ´ëÇÑ °íÂû°ú ½ÃÀå ¿¹Ãø µîÀÇ Á¤º¸¸¦ ÀüÇØµå¸³´Ï´Ù.

¸ñÂ÷

Á¦1Àå º¸°í¼­ ¼­·Ð

Á¦2Àå PPD¿ë ZULRESSO °³¿ä

Á¦3Àå °æÀï ±¸µµ(Ãâ½Ã Ä¡·á¹ý)

Á¦4Àå °æÀï ±¸µµ(ÈÄ±â ½Å±Ô Ä¡·á¹ý)

Á¦5Àå PPD¿ë ZULRESSO ½ÃÀå Æò°¡

Á¦6Àå SWOT ºÐ¼®

Á¦7Àå ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ

Á¦8Àå ºÎ·Ï

Á¦9Àå DelveInsightÀÇ ¼­ºñ½º ³»¿ë

Á¦10Àå ¸éÃ¥»çÇ×

Á¦11Àå DelveInsight¿¡ ´ëÇØ

Á¦12Àå º¸°í¼­ ±¸ÀÔ ¿É¼Ç

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

“"ZULRESSO Drug Insight and Market Forecast - 2032" report provides comprehensive insights about ZULRESSO for postpartum depression (PPD) in the United States. A detailed picture of the ZULRESSO for PPD in the United States for the study period 2019 -2032 is provided in this report along with a detailed description of the ZULRESSO for PPD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZULRESSO market forecast analysis for PPD in the US, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in PPD.

Drug Summary:

ZULRESSO (brexanolone) is a neuroactive steroid gamma-aminobutyric acid (GABA), a receptor-positive modulator indicated for treating PPD in adults. ZULRESSO was granted a Priority Review and was designated a breakthrough treatment by the FDA. ZULRESSO is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. The mechanism of action of brexanolone in the treatment of PPD in adults is related to its positive allosteric modulation of GABAA receptors. ZULRESSO potentiated GABA-mediated currents from recombinant human GABAA receptors in mammalian cells expressing α1B2γ2 receptor subunits, α4B3¥ä receptor subunits, and α6B3¥ä receptor subunits. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults.

Scope of the Report:

The report provides insights into:

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZULRESSO Analytical Perspective by DelveInsight

In-depth ZULRESSO Market Assessment

This report provides a detailed market assessment of ZULRESSO for postpartum depression (PPD) in the United States. This segment of the report provides forecasted sales data from 2023 to 2032.

ZULRESSO Clinical Assessment

The report provides the clinical trials information of ZULRESSO for PPD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

Key Questions:

Table of Contents

1. Report Introduction

2. ZULRESSO Overview in PPD

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ZULRESSO Market Assessment

6. SWOT Analysis

7. Analysts' Views

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â